Silo pharma announces positive results for novel spc-15 treatment targeting stress-related disorders

Dual-action approach combining 5-ht4r agonist (spc-15) and nmdar antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions

SILO Ratings Summary

SILO Quant Ranking